Summary
The multiple dose pharmacokinetics of isotretinoin and its major blood metabolite, 4-oxo-isotretinoin, were studied in 10 patients with cystic acne and 11 patients with various keratinization disorders. Blood samples were obtained at predetermined times following the first dose, interim doses and the final dose. Blood concentrations of isotretinoin and 4-oxo-isotretinoin were measured by a specific and sensitive HPLC method. A lag time was usually observed prior to the onset of absorption following oral administration of the drug in a soft elastic gelatin capsule. Absorption then proceeded rapidly and maximum blood concentrations usually occurred within 4 h of drug administration. The harmonic mean half-life for the elimination of isotretinoin by the cystic acne patients was approximately 10 h after the initial dose and did not change significantly following 25 days of 40 mg b.i.d. dosing. Steady-state blood concentrations remained relatively constant after the fifth day of dosing. The harmonic mean elimination half-life in the patients with various disorders of keratinization was about 16 h. The results of the 2 studies suggest that no significant changes in the pharmacokinetics of isotretinoin occur during multiple dosing and that the multiple dose pharmacokinetic profile is predictable and can be described using a linear pharmacokinetic model. This suggests that the steady-state concentrations of isotretinoin can be predicted from single dose data.
Similar content being viewed by others
References
Farrell LN, Strauss MD, Strainer BS (1980) The treatment of severe cystic acne with 13-cis-retinoic acid. J Am Acad Dermatol 3: 602–611
Peck GL, Olsen TG, Yoder FW, Strauss JS, Downing DT, Pandya M, Butkus D, Arnaud-Battandier J (1979) Prolonged remissions of cystic acne and conglobate acne with 13-cis-retinoic acid. N Engl J Med 300: 329–333
Peck GL, Yoder FW (1976) Treatment of lamellar ichthyosis and other keratinising dermatoses with an oral synthetic retinoid. Lancet 2: 1172
Peck GL, Yoder FW, Olsen TG, Pandya MD, Butkus D (1978) Treatment of Dariers disease, lamellar ichthycsis, pityriasis ruba pilaris, cystic acne and basal cell carcinoma with oral 13-cis-retinoic acid. Dermatologica 157: 11–12
Colburn WA, Vane FM, Shorter HJ (1983) Pharmacokinetics of isotretinoin and its major blood metabolite, 4-oxo-isotretinoin, following a single oral dose to man. Eur J Clin Pharmacol 24: (in press)
Khoo K-C, Reik FD, Colburn WA (1982) Pharmacokinetic profile of isotretinoin following a single oral dose to normal man. J Clin Pharmacol 22: 395–402
Vane FM, Stoltenborg JK, Buggé CJL (1982) Determination of 13-cis-retinoic acid and its major metabolite, 4-oxo-13-cis-retinoic acid, in human blood by reverse-phase high performance liquid chromatography. J Chromatogr 227: 471–484
Metzler CM, Elfring GL, McEwen A (1974) Package of computer programs for pharmacokinetic modeling. Biometrics 30: 562–563
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brazzell, R.K., Vane, F.M., Ehmann, C.W. et al. Pharmacokinetics of isotretinoin during repetitive dosing to patients. Eur J Clin Pharmacol 24, 695–702 (1983). https://doi.org/10.1007/BF00542225
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00542225